This data set provides an estimate of the number of people living with Human Immunodeficiency Virus (HIV) Disease at the end of each year for 2012 through 2016 and the number of these persons who have injection drug use identified as the primary risk for having acquired the infection. The data sets also provides the number of new diagnoses of HIV Disease by county among all persons and among those with injection drug identified as the primary risk. These data are derived through HIV surveillance activities of the Pennsylvania Department of Health. Laboratories and providers are required to report HIV test results for all individuals with a result that indicates the presence of HIV infection. These include detectable viral load results and CD4 results below 200 cells. These data are reported electronically to the Pennsylvania National Electronic Disease Surveillance System. The most recent patient address information obtained from all reports (both HIV and non-HIV reports) is used to identify last known county of residence in 2016. Cases are also matched to lists that identify individuals who have been reported to be living outside of Pennsylvania by the US Centers for Disease Control and Prevention (CDC) to remove cases that are presumed to have moved from Pennsylvania. Address data for Philadelphia County cases are extracted from the Pennsylvania enhanced HIV/AIDS Reporting System.

IDU: use of non-prescribed injection drugs (e.g., heroin, fentanyl, cocaine, etc.)

HIV Disease: Confirmed infection with the Human Immunodeficiency Virus (HIV). Acquired Immunodeficiency Syndrome (AIDS) is a stage of HIV Disease marked by a low CD4 count and/or certain co-morbid conditions.

Vaccine Rates by US House Districts – Contains aggregate counts of partially and fully COVID-19 vaccinated people as reported through the Pennsylvania Statewide Immunization Information System (PA SIIS), along with percent of population calculations for the US House Districts. To assign districts, records were geocoded to the street address or to ZIP code centroid when street addressed failed. Aggregate case counts of 1 through 4 for each district are suppressed and displayed as a null value.

This data set provides an estimate of the number of people aged 15-34 years with newly identified confirmed chronic (or past/present) hepatitis C infection, by county and by year.
The dataset is limited to persons aged 15 to 34 because hepatitis C infection is usually asymptomatic for decades after infection occurs. Cases are usually identified because they have finally become symptomatic, or they were screened. Until very recently, screening for hepatitis C was not routinely performed. This makes it very challenging to identify persons with recent infection. Limiting the age of newly identified patients to 15-34 years makes it more likely that the cases included in the dashboard were infected fairly recently. It is not meant to imply that the opioid crisis’ effect on hepatitis C transmission is limited to younger people.
The process by which case counts are determined is as follows: Case reports, which include lab test results and address data, are sent to Pennsylvania’s electronic disease surveillance system (PA-NEDSS). Confirmation status is determined by public health investigators who evaluate test results against the CDC case definition for hepatitis C in place for the year in which the patient was first reported (https://wwwn.cdc.gov/nndss/conditions/hepatitis-c-chronic/). Reportable disease data, including hepatitis C, is extracted from PA-NEDSS, combined with similar data sent by the Philadelphia Department of Public Health (PDPH, which uses a separate surveillance system), and sent to CDC. Case data sent to CDC (from PA-NEDSS and PDPH combined) are used to create a statewide reportable disease dataset. This statewide file was used to generate the dashboard dataset.
Note that the term that CDC has used to denote persons with hepatitis C infection that is not known to be acute has switched back and forth between “Hepatitis C, past or present” and “Hepatitis C, chronic” over the past several years. The CDC case definition for hepatitis C, chronic (or past or present) changed in 2005, 2010, 2011, 2012, and 2016. Persons reported as confirmed in one year may not have been considered confirmed in another year. For example, patients with a positive radioimmunoblot assay (RIBA) or elevated enzyme immunoassay (EIA) signal-to-cutoff level were counted as confirmed in 2012, but not counted as confirmed in 2016.
Data sent to CDC’s National Notifiable Disease Surveillance System use a measure for aggregating cases by year called the MMWR year. The MMWR, or the Morbidity and Mortality Weekly Report, is an official publication by CDC and the means by which CDC has historically presented aggregated case count data. Since data in the MMWR are presented by week, the MMWR year always starts on the Sunday closest to Jan 1 and ends on the Saturday closest to Dec 31. The most recent year for which case counts are finalized is 2016. Annual case counts are finalized in May of the following year.
The patient zip code, as submitted to PA-NEDSS, is used to determine the case’s county of residence at the time of initial case report. In some instances, the patient zip code is unavailable. In those circumstances, the zip code of the provider that ordered the lab test is used as a proxy for patient zip code.
Users should note that the state prison system routinely screens all incoming inmates for hepatitis C. If these inmates are determined to be confirmed cases, they are assigned to the county in which they were incarcerated when their confirmed hepatitis C was first identified. Hepatitis C case counts in counties with state prisons should be interpreted cautiously in light of this enhanced screening activity.

View quarterly trends in buprenorphine dispensation data. Please note that buprenorphine data received by the PDMP is restricted to prescriptions filled by pharmacies. The PDMP does not collect information on the reason a controlled substance is prescribed, nor does it collect data from substance abuse treatment facilities or dispensing prescribers providing buprenorphine for substance abuse treatment. Buprenorphine is sometimes prescribed off-label for pain. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

This dataset contains counts of COVID-19 deaths by age by county. Suppression applies for quantities less than 5.

Data only includes information reported to EDRS, the Electronic Death Reporting System.
Data usually updated each Friday.

View annual counts of Accidental or Undetermined overdose deaths for 2012 forward, including provisional estimates of annual counts of overdose deaths for recent years, as noted with an asterisk and the month the data was pulled.
NOTE: Finalized death records for overdose deaths are often delayed by 3-6 months. Counties labeled “no value” have data suppressed because the counts are between 1 and 9.

- Overdose Deaths are classified using the International Classification of Diseases, Tenth Revision (ICD–10). Drug-poisoning deaths are identified using underlying cause-of-death codes X40–X44, and Y10–Y14, and include the following:

- R99 when the Injury Description indicates an overdose death.

- X49 when literal COD is Mixed or Combined or Multiple Substance Toxicity, as these are likely drug overdoses

- X47 when substance indicated is difluoroethane, alone or in combination with other drugs

- Source Pennsylvania Prescription Drug Monitoring Program*

* These data were supplied by the Bureau of Health Statistics and Registries, Harrisburg, Pennsylvania. The Bureau of Health Statistics and Registries specifically disclaims responsibility for any analyses, interpretations or conclusions.

- Estimates are broken down by type of drugs involved in the overdose

- Any Drug Overdose Death - all drug overdose deaths, regardless of type of drug involved, excluding alcohol only deaths

- Opioid Overdose Death - any overdose death involving opioids, prescription or illegal

This indicator includes the count and rate of new HIV diagnoses among individuals using injection drugs per 100,000 individuals estimated to have Drug Use Disorder.

Aggregate counts of partially and fully COVID-19 vaccinated people as reported through the Pennsylvania Statewide Immunization Information System (PA SIIS), along with percent of population calculations for the US House Districts. To assign districts, records were geocoded to the street address or to ZIP code centroid when street addressed failed. Aggregate case counts of 1 through 4 for each district are suppressed and displayed as a null value. District value displayed as null when for records that could not be allocated to a district.
Note: Pennsylvania residents who receive a COVID vaccine from a clinic in Philadelphia County, or received a vaccination from a federal facility (such as a veterans hospital or federal prison), or who received a vaccination in another state are not included in this map due to separate reporting requirements. Percentages are based on total population estimates (including children) from the US Census Bureau for each legislative district. For more information, please view the technical notes on the COVID-19 Dashboard.

This dataset contains information on the number of doses given for Naloxone throughout the Commonwealth of Pennsylvania by County. If the Incident County FIPS Code column is blank it means Not Recorded, as this field was blank by the Patient Care Report (PCR) vendor or the EMS Provider. Data is updated Quarterly starting with the first Quarter of Calendar Year 2018.

View quarterly trends in opioid dispensation data for all Schedule II-V opioids.
Please see PDMP Data Technical Notes for additional details: http://www.health.pa.gov/Your-Department-of-Health/Offices%20and%20Bureaus/PaPrescriptionDrugMonitoringProgram/Documents/PDMPDataTechnicalNotes.pdf
More information from U.S. Department of Justice
https://www.deadiversion.usdoj.gov/schedules/
Schedule I Controlled Substances
Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.
Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy").
Schedule II/IIN Controlled Substances (2/2N)
Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence.
Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone.
Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®).
Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital.
Schedule III/IIIN Controlled Substances (3/3N)
Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence.
Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®).
Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone.
Schedule IV Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances in Schedule III.
Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®).
Schedule V Controlled Substances
Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics.
Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.